INDV Quote, Financials, Valuation and Earnings

Nephros, Inc. has a net margin of 13.38% compared to Indivior PLC's net margin of 7.07%. Indivior PLC's return on equity of 14.29% beat Nephros, Inc.'s return on equity of 16.22%.

Indivior PLC has a consensus price target of $37.86, signalling upside risk potential of 4.69%. On the other hand Nephros, Inc. has an analysts' consensus of $6.50 which suggests that it could grow by 24.28%. Given that Nephros, Inc. has higher upside potential than Indivior PLC, analysts believe Nephros, Inc. is more attractive than Indivior PLC.

Indivior PLC has a beta of 1.102, which suggesting that the stock is 10.185% more volatile than S&P 500. In comparison Nephros, Inc. has a beta of 1.483, suggesting its more volatile than the S&P 500 by 48.288%.

Indivior PLC has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Nephros, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Indivior PLC pays -- of its earnings as a dividend. Nephros, Inc. pays out -- of its earnings as a dividend.

Indivior PLC quarterly revenues are $314M, which are larger than Nephros, Inc. quarterly revenues of $4.8M. Indivior PLC's net income of $42M is higher than Nephros, Inc.'s net income of $337K. Notably, Indivior PLC's price-to-earnings ratio is 36.00x while Nephros, Inc.'s PE ratio is 37.87x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Indivior PLC is 3.87x versus 3.14x for Nephros, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Owlet, Inc. has a net margin of 13.38% compared to Indivior PLC's net margin of 12.58%. Indivior PLC's return on equity of 14.29% beat Owlet, Inc.'s return on equity of --.

Indivior PLC has a consensus price target of $37.86, signalling upside risk potential of 4.69%. On the other hand Owlet, Inc. has an analysts' consensus of $14.88 which suggests that it could fall by -2.59%. Given that Indivior PLC has higher upside potential than Owlet, Inc., analysts believe Indivior PLC is more attractive than Owlet, Inc..

Indivior PLC has a beta of 1.102, which suggesting that the stock is 10.185% more volatile than S&P 500. In comparison Owlet, Inc. has a beta of 1.734, suggesting its more volatile than the S&P 500 by 73.364%.

Indivior PLC has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Owlet, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Indivior PLC pays -- of its earnings as a dividend. Owlet, Inc. pays out -- of its earnings as a dividend.

Indivior PLC quarterly revenues are $314M, which are larger than Owlet, Inc. quarterly revenues of $32M. Indivior PLC's net income of $42M is higher than Owlet, Inc.'s net income of $4M. Notably, Indivior PLC's price-to-earnings ratio is 36.00x while Owlet, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Indivior PLC is 3.87x versus 2.56x for Owlet, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Pfizer Inc. has a net margin of 13.38% compared to Indivior PLC's net margin of 21.32%. Indivior PLC's return on equity of 14.29% beat Pfizer Inc.'s return on equity of 10.84%.

Indivior PLC has a consensus price target of $37.86, signalling upside risk potential of 4.69%. On the other hand Pfizer Inc. has an analysts' consensus of $28.62 which suggests that it could grow by 14.36%. Given that Pfizer Inc. has higher upside potential than Indivior PLC, analysts believe Pfizer Inc. is more attractive than Indivior PLC.

Indivior PLC has a beta of 1.102, which suggesting that the stock is 10.185% more volatile than S&P 500. In comparison Pfizer Inc. has a beta of 0.457, suggesting its less volatile than the S&P 500 by 54.271%.

Indivior PLC has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Pfizer Inc. offers a yield of 6.87% to investors and pays a quarterly dividend of $0.43 per share. Indivior PLC pays -- of its earnings as a dividend. Pfizer Inc. pays out 119.94% of its earnings as a dividend.

Indivior PLC quarterly revenues are $314M, which are smaller than Pfizer Inc. quarterly revenues of $16.7B. Indivior PLC's net income of $42M is lower than Pfizer Inc.'s net income of $3.6B. Notably, Indivior PLC's price-to-earnings ratio is 36.00x while Pfizer Inc.'s PE ratio is 14.59x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Indivior PLC is 3.87x versus 2.28x for Pfizer Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Viatris, Inc. has a net margin of 13.38% compared to Indivior PLC's net margin of -3.41%. Indivior PLC's return on equity of 14.29% beat Viatris, Inc.'s return on equity of -21.75%.

Indivior PLC has a consensus price target of $37.86, signalling upside risk potential of 4.69%. On the other hand Viatris, Inc. has an analysts' consensus of $12.1250 which suggests that it could fall by -0.94%. Given that Indivior PLC has higher upside potential than Viatris, Inc., analysts believe Indivior PLC is more attractive than Viatris, Inc..

Indivior PLC has a beta of 1.102, which suggesting that the stock is 10.185% more volatile than S&P 500. In comparison Viatris, Inc. has a beta of 0.843, suggesting its less volatile than the S&P 500 by 15.721%.

Indivior PLC has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Viatris, Inc. offers a yield of 3.92% to investors and pays a quarterly dividend of $0.12 per share. Indivior PLC pays -- of its earnings as a dividend. Viatris, Inc. pays out 90.63% of its earnings as a dividend. Viatris, Inc.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Indivior PLC quarterly revenues are $314M, which are smaller than Viatris, Inc. quarterly revenues of $3.8B. Indivior PLC's net income of $42M is higher than Viatris, Inc.'s net income of -$128.2M. Notably, Indivior PLC's price-to-earnings ratio is 36.00x while Viatris, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Indivior PLC is 3.87x versus 1.03x for Viatris, Inc.. Usually stocks with elevated PS ratios are considered overvalued.